SEC Company Response from vTv Therapeutics Inc. (VTVT) (CIK 0001641489) (VTVT) — Mar 15, 2018
vTv Therapeutics Inc. (VTVT) (CIK 0001641489)
Date: March 15, 2018 · CIK: 0001641489 · Accession: 0000950142-18-000643
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-223269
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Attention: Chris Edwards vTv Therapeutics Inc. Registration Statement on Form S‑3 (File No. 333-223269)
Dear Mr. Edwards:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 (the “S-3”) of vTv Therapeutics Inc. (the “Company”) be accelerated to March 19, 2018 at 4:00 p.m. Eastern Time or as soon thereafter as may be practicable.
We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Lawrence G. Wee of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3052.
*****
Very truly yours,
VTV THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm vTv Therapeutics Inc. 4170 Mendenhall Oaks Pkwy High Point, NC 27265 March 15, 2018 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards vTv Therapeutics Inc. Registration Statement on Form S‑3 (File No. 333-223269) Dear Mr. Edwards: Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 (the “S-3”) of vTv Therapeutics Inc. (the “Company”) be accelerated to March 19, 2018 at 4:00 p.m. Eastern Time or as soon thereafter as may be practicable. We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Lawrence G. Wee of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3052. ***** Very truly yours, VTV THERAPEUTICS INC. By: /s/ Rudy Howard Name: Rudy Howard Title: Chief Financial Officer